atorvastatin has been researched along with Cerebrovascular Disorders in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, X; Wang, L | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Alonso-Canovas, A; Chico-García, JL; Cruz-Culebras, A; de Felipe Mimbrera, A; García-Madrona, S; Gómez-López, A; Masjuan, J; Matute-Lozano, C; Natera-Villalba, E; Ros-Castelló, V; Sánchez-Sánchez, A; Vera-Lechuga, R | 1 |
| Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y | 1 |
| Guan, L; Hou, D; Ji, Y; Li, B; Li, W; Liu, C; Mei, Y; Ren, C; Sun, Z; Wu, H; Zhang, H | 1 |
| Choi, CU; Kim, IW; Kim, JH; Kim, K; Kwak, A; Oh, JM | 1 |
| de Oliveira, RM; Ferreira, ED; Godinho, J; Milani, H; Previdelli, IS; Ribeiro, MH; Zaghi, GG | 1 |
| Cheng, G; Li, H; Li, R; Sun, S; Wang, C; Zhang, S; Zou, M | 1 |
| Abbassi, MM; Elkaffas, S; Elmarsafawi, AG; Elsawy, HM; Sabry, NA | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Amarenco, P; Brenner, D; Gongora-Rivera, F; Jaramillo, A; Klein, IF; Labreuche, J; Lavallée, PC; Touboul, PJ; Vicaut, E | 1 |
| Tsuda, K | 1 |
| Myint, PK; Niruban, A; Potter, JF | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Lavie, CJ; Milani, RV | 1 |
| Teramoto, T | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| Davalos, A; Fisher, M | 1 |
| Alexy, T; Czopf, J; Habon, T; Horvath, B; Juricskay, I; Kesmarky, G; Koltai, K; Marton, Z; Szapary, L; Szots, M; Toth, K | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Candura, D; Chello, M; Covino, E; D'Ambrosio, A; Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Barter, P; Breazna, A; Carter, R; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Waters, DD | 1 |
| Cachofeiro, V; Lahera, V | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
4 review(s) available for atorvastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Randomized Controlled Trials as Topic; Risk | 2016 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Emerging therapies for cerebrovascular disorders.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Pyrroles; Randomized Controlled Trials as Topic; Risk; Simvastatin; Therapeutics; Tissue Plasminogen Activator; Treatment Outcome | 2004 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
6 trial(s) available for atorvastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Efficacy of Different Perioperative Statin Regimens on Protection Against Post-Coronary Artery Bypass Grafting Major Adverse Cardiac and Cerebral Events.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cerebrovascular Disorders; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Creatine Kinase; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Perioperative Care; Prospective Studies; Quality of Life; Troponin I | 2016 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Stenosis; Cerebrovascular Disorders; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
Topics: Aged; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Cardiac Surgical Procedures; Cerebrovascular Disorders; Female; Heart Diseases; Heptanoic Acids; Humans; Length of Stay; Male; Middle Aged; Postoperative Complications; Pyrroles | 2006 |
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2006 |
14 other study(ies) available for atorvastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.
Topics: Activities of Daily Living; Anticholesteremic Agents; Aspirin; Atorvastatin; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Cholesterol, LDL; Ezetimibe; Humans; Leptin; Pyrroles; Treatment Outcome; Triglycerides | 2022 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cerebrovascular Disorders; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Recurrence; Retrospective Studies; Secondary Prevention; Tablets; Tertiary Care Centers; Time Factors; Treatment Outcome | 2020 |
[Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world].
Topics: Aspirin; Atorvastatin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginkgo biloba; Hospital Information Systems; Humans; Ischemia; Medicine, Chinese Traditional; Plant Extracts | 2017 |
Congenital internal carotid artery hypoplasia: Case report.
Topics: Angiography, Digital Subtraction; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Cerebrovascular Disorders; Clopidogrel; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Speech Disorders; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance Benefits; Insurance, Health; Male; Protective Factors; Retrospective Studies; Rosuvastatin Calcium; Secondary Prevention | 2019 |
Robust and enduring atorvastatin-mediated memory recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats.
Topics: Aging; Amnesia, Retrograde; Animals; Atorvastatin; Brain; Cerebrovascular Disorders; Chronic Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Maze Learning; Memory; Nootropic Agents; Pyramidal Cells; Rats, Wistar; Treatment Outcome | 2016 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Statins and gender-related difference in endothelial function in cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
High-dose atorvastatin in acute coronary and cerebrovascular syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cerebrovascular Disorders; Coronary Circulation; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2010 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Topics: Aged; Atorvastatin; Cerebral Hemorrhage; Cerebrovascular Disorders; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Pyrroles; Time Factors | 2004 |
Specific amelioration of cerebral endothelial dysfunction in hypertensive patients treated with atorvastatin.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles | 2008 |